Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer immunotherapy

An armed oncolytic virus for GBM destruction

Nature Cancer volume 3, pages 1274–1276 (2022)Cite this article

Subjects

Immunovirotherapy is a promising therapeutic strategy for glioblastoma (GBM), a deadly tumor for which effective treatments remain a clinical need. A new study describes an oncolytic herpes simplex virus (oHSV) armed with a bispecific anti-EGFR–CCL5 fusion protein that activates innate and adaptive antitumor immune responses that are highly efficacious in preclinical GBM models.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The multifaceted effects of OV–cmab–CCL5 infection on a GBM tumor.

References

  1. Burster, T. et al. Front. Cell Dev. Biol. 9, 695325 (2021).

    Article  Google Scholar 

  2. Himes, B. T. et al. Front. Oncol. 11, 770561 (2021).

    Article  Google Scholar 

  3. Medikonda, R. et al. J. Neurooncol. 151, 41–53 (2021).

    Article  Google Scholar 

  4. Yeo, E. C. F. et al. Cells 10, 607 (2021).

    Article  CAS  Google Scholar 

  5. Cai, W. Q. et al. Front. Oncol. 10, 1249 (2020).

    Article  Google Scholar 

  6. Tian, L. et al. Nat. Cancer https://doi.org/10.1038/s43018-022-00448-0 (2022).

    Article  Google Scholar 

  7. Jahan, N. et al. Viruses 13, 1740 (2021).

    Article  CAS  Google Scholar 

  8. Friedman, G. K. et al. N. Engl. J. Med. 384, 1613–1622 (2021).

    Article  CAS  Google Scholar 

  9. Todo, T. et al. Nat. Med. 28, 1630–1639 (2022).

    Article  CAS  Google Scholar 

  10. Totsch, S. K. et al. Oncogene 38, 6159–6171 (2019).

    Article  CAS  Google Scholar 

  11. Bausart, M., Preat, V. & Malfanti, A. J. Exp. Clin. Cancer Res. 41, 35 (2022).

    Article  CAS  Google Scholar 

  12. Koch, M. S., Lawler, S. E. & Chiocca, E. A. Cancers 12, 3514 (2020).

    Article  CAS  Google Scholar 

  13. Kranjc, M. K. et al. Radiol. Oncol. 53, 397–406 (2019).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    Judit Sanchez Gil & Samuel D. Rabkin

Authors
  1. Judit Sanchez Gil
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samuel D. Rabkin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samuel D. Rabkin.

Ethics declarations

Competing interests

S.D.R. is a co-inventor on patents relating to oHSVs owned and managed by Georgetown University and Massachusetts General Hospital, which have received royalties from Amgen and ActiVec Inc. J.S.G. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sanchez Gil, J., Rabkin, S.D. An armed oncolytic virus for GBM destruction. Nat Cancer 3, 1274–1276 (2022). https://doi.org/10.1038/s43018-022-00457-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-022-00457-z

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer